Skip to main content

Evotaz and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with Evotaz (atazanavir / cobicistat).

Minor

Caffeine atazanavir

Minor Drug Interaction

Information for this minor interaction is available on the professional version.

Moderate

atazanavir food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Administration of atazanavir with food enhances oral bioavailability and reduces pharmacokinetic variability. According to the manufacturer, administration with a light meal increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of a single 400 mg dose of atazanavir by 57% and 70%, respectively, relative to the fasting state. Administration with a high-fat meal resulted in a mean increase of 35% in atazanavir AUC and no change in Cmax compared to fasting. The coefficient of variation of AUC and Cmax decreased by approximately one-half when given with either a light or high-fat meal compared to the fasting state.

MANAGEMENT: To ensure maximal oral absorption, atazanavir should be administered with or immediately after a meal.

References

  1. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb (2003):
Moderate

High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Moderate plausibility

PIs - hyperlipidemia

Treatment with ritonavir alone or in combination with other protease inhibitors (e.g., lopinavir, saquinavir, tipranavir, fosamprenavir) has resulted in substantial increases in the concentration of total cholesterol and triglycerides. These effects have also been reported with other protease inhibitors but may be the most dramatic with ritonavir. The clinical significance of these elevations is unclear. Marked elevation in triglyceride levels is a risk factor for development of pancreatitis. Triglyceride and cholesterol testing is recommended before starting ritonavir (with or without other protease inhibitors) and periodically during therapy. Lipid disorders should be managed as clinically appropriate.

References

  1. "Product Information. Norvir (ritonavir)." AbbVie US LLC SUPPL-25 (2022):
  2. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb SUPPL-44 (2020):
  3. "Product Information. Lexiva (fosamprenavir)." ViiV Healthcare SUPPL-41 (2019):
  4. "Product Information. Kaletra (lopinavir-ritonavir)." AbbVie US LLC SUPPL-54 (2020):
  5. "Product Information. Invirase (saquinavir)." Roche Laboratories SUPPL-25 (2020):
  6. "Product Information. Aptivus (tipranavir)." Boehringer Ingelheim SUPPL-21 (2020):
View all 6 references

Evotaz drug interactions

There are 618 drug interactions with Evotaz (atazanavir / cobicistat).

Evotaz disease interactions

There are 9 disease interactions with Evotaz (atazanavir / cobicistat) which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.